"That's why we are also excited to announce that the company will continue to fund the UCB U.S. Myasthenia Gravis Scholarship into 2026." "Financially, I face significant challenges as I juggle ...

Bringing this interview with Marla Black Morgan, MD, to a close, she looks to the future of research in both myasthenia ...

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...

In today’s Health Headlines, June is Myasthenia Gravis Awareness Month. What is myasthenia gravis, how is it diagnosed, and ...

Rare disease community members take action in June to spread awareness and advocate for better treatments and a cure for myasthenia gravis The global MG Community is turning Awareness into Action ...

ATLANTA, June 17, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that 15 scholarships were awarded to people impacted by myasthenia gravis in the U.S. The UCB ...

"That's why we are also excited to announce that the company will continue to fund the UCB U.S. Myasthenia Gravis Scholarship into 2026." "Financially, I face significant challenges as I juggle the ...

OTTAWA — Established treatments such as thymectomy and steroids remain mainstays in the management of myasthenia gravis (MG), according to a presentation at the Canadian Neurological Sciences ...

Andy Stephenson, from Doncaster, has myasthenia gravis and has been admitted to hospital 32 times because muscles involved in his breathing stopped working. But since taking the drug efgartigimod ...

MG is an acquired antibody-mediated rare autoimmune disorder affecting the neuromuscular junction. According to the Myasthenia Gravis Foundation of America (MGFA) and various studies, its global ...